National Planning Corporation’s Acadia Pharmaceuticals ACAD Stock Holding History

National Planning Corporation’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-33,580	Closed	-$1.26M	–	53
2017 Q3	$1.26M	Sell	33,580 -1,100	-3%	-$35.8K	0.11%	200
2017 Q2	$987K	Buy	34,680 +2,500	+8%	+$74.5K	0.08%	258
2017 Q1	$1.08M	Buy	32,180 +1,900	+6%	+$67.1K	0.08%	229
2016 Q4	$1.07M	Sell	30,280 -400	-1%	-$10.6K	0.08%	223
2016 Q3	$705K	Buy	30,680 +1,500	+5%	+$50.9K	0.06%	287
2016 Q2	$1.07M	Sell	29,180 -50	-0.2%	-$1.67K	0.08%	230
2016 Q1	$808K	Buy	+29,230	New	+$637K	0.07%	270
2015 Q1	–	Sell	-1,200	Closed	-$38.6K	–	653
2014 Q4	$38.6K	Buy	+1,200	New	+$34K	﹤0.01%	1392

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

National Planning Corporation's ACAD Position: Q4 2017 in Review

National Planning Corporation sold out of Acadia Pharmaceuticals (ACAD) in Q4 2017, closing a stake of 33,580 shares — an estimated $1.26M sold.

National Planning Corporation first reported a position in ACAD in Q4 2014 and held it in 8 quarters. The position peaked at $1.26M in Q3 2017. 210 funds tracked by Wall St. Rank hold ACAD as of Q4 2017.

National Planning Corporation reported no remaining Acadia Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
National Planning Corporation sold 33,580 Acadia Pharmaceuticals shares in Q4 2017, an estimated $1.26M.
National Planning Corporation first reported a position in Acadia Pharmaceuticals in Q4 2014 and held it in 8 quarters.
National Planning Corporation's Acadia Pharmaceuticals position peaked at $1.26M in Q3 2017.
210 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.